The Environment Is a Key Factor in Determining the Anti-Amyloid Efficacy of EGCG
Open Access
- 11 December 2019
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 9 (12), 855
- https://doi.org/10.3390/biom9120855
Abstract
Millions of people around the world suffer from amyloid-related disorders, including Alzheimer’s and Parkinson’s diseases. Despite significant and sustained efforts, there are still no disease-modifying drugs available for the majority of amyloid-related disorders, and the overall failure rate in clinical trials is very high, even for compounds that show promising anti-amyloid activity in vitro. In this study, we demonstrate that even small changes in the chemical environment can strongly modulate the inhibitory effects of anti-amyloid compounds. Using one of the best-established amyloid inhibitory compounds, epigallocatechin-3-gallate (EGCG), as an example, and two amyloid-forming proteins, insulin and Parkinson’s disease-related -synuclein, we shed light on the previously unexplored sensitivity to solution conditions of the action of this compound on amyloid fibril formation. In the case of insulin, we show that the classification of EGCG as an amyloid inhibitor depends on the experimental conditions select, on the method used for the evaluation of the efficacy, and on whether or not EGCG is allowed to oxidise before the experiment. For -synuclein, we show that a small change in pH value, from 7 to 6, transforms EGCG from an efficient inhibitor to completely ineffective, and we were able to explain this behaviour by the increased stability of EGCG against oxidation at pH 6.
Funding Information
- Novo Nordisk Fonden (-)
This publication has 83 references indexed in Scilit:
- The amyloid cascade and Alzheimer's disease therapeutics: theory versus observationLaboratory Investigation, 2019
- Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last DecadeAnnual Review of Biochemistry, 2017
- The amyloid hypothesis of Alzheimer's disease at 25 yearsEMBO Molecular Medicine, 2016
- Immunotherapeutic Approaches for Alzheimer’s DiseaseNeuron, 2015
- Inhibition of protein aggregation and amyloid formation by small moleculesCurrent Opinion in Structural Biology, 2015
- The amyloid state and its association with protein misfolding diseasesNature Reviews Molecular Cell Biology, 2014
- Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy for protein misfolding diseasesBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Atomic structure and hierarchical assembly of a cross-β amyloid fibrilProceedings of the National Academy of Sciences of the United States of America, 2013
- Alzheimer's disease: clinical trials and drug developmentThe Lancet Neurology, 2010
- Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition MechanismChemical Biology & Drug Design, 2005